


## Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

### Supplementary Materials




#### SUPPLEMENTARY METHODS

##### Colony forming assays


Exponentially growing CT26 cells were plated at densities of  $1 \times 10^2$  to  $2.4 \times 10^3$  well. 24 h later, cells were treated with a range of concentrations between 0 and 10  $\mu$ M DSR-29133 followed 2 h later by X-ray radiation treatment with 0, 2 or 4 Gy. Media were replaced 24 h later, or left unchanged, and cells were left to proliferate for 7 days or until colonies of  $\sim 50$  cells were present in the untreated wells. Colonies were stained with 0.5 % (w/v) methylene blue solution and counted manually. Surviving fractions were normalised to the non-irradiated control or in the case of experiments not involving radiation, the untreated control.




**Supplementary Figure S1: DSR-29133 is active against the mouse TLR7 receptor.** A, NF $\kappa$ B gene reporter assays were performed in HEK293 cells transfected with either murine TLR7 (0.001–10  $\mu$ M) of DSR-29133. Data expressed as mean  $\pm$  SEM. Data are representative of at least 2 independent experiments.



**Supplementary Figure S2: DSR-29133 is well tolerated following intravenous administration.** (A) CT26, (B) Renca (both Balb/c) and (C) LM8 (C3H) tumor bearing mice received weekly i.v. injections of DSR-29133 at a dose of 0.1 (Renca and LM8) or 1 mg/kg (CT26) for 3 weeks. Individual mouse weight plotted.



**Supplementary Figure S3: DSR-29133 leads to a dose-dependent reduction in Renca tumor volume following intravenous administration.** Renca tumor bearing (Balb/c) mice received weekly i.v. injections of DSR-29133 at doses of 0.0125–0.1 mg/kg for 3 weeks. Data expressed as mean  $\pm$  SEM. Experimental groups contained at least 5 mice. \* $P < 0.05$  (Mann-Whitney test) when compared to NT cohort.



**Supplementary Figure S4: DSR-29133 does not alter tumor cell clonogenic potential or radiosensitivity of CT26 cells.** (A) Colony forming assays using 0.01–10µM DSR-29133 does not affect tumor cell clonogenicity when added to the culture medium either for 24 hours or for the duration of the experiment. (B) Addition of DSR-29133 does not impact the radiosensitivity of CT26 cells. Data expressed as mean ± SEM. Data are representative of at least 2 independent experiments.